Your browser doesn't support javascript.
loading
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
Perelli, Luigi; Carbone, Federica; Zhang, Li; Huang, Justin K; Le, Courtney; Khan, Hania; Citron, Francesca; Del Poggetto, Edoardo; Gutschner, Tony; Tomihara, Hideo; Soeung, Melinda; Minelli, Rosalba; Srinivasan, Sanjana; Peoples, Michael; Lam, Truong Nguyen Anh; Lundgren, Sebastian; Xia, Ruohan; Zhu, Cihui; Mohamed, Alaa M T; Zhang, Jianhua; Sircar, Kanishka; Sgambato, Alessandro; Gao, JianJun; Jonasch, Eric; Draetta, Giulio F; Futreal, Andrew; Bakouny, Ziad; Van Allen, Eliezer M; Choueiri, Toni; Signoretti, Sabina; Msaouel, Pavlos; Litchfield, Kevin; Turajlic, Samra; Wang, Linghua; Chen, Ying Bei; Di Natale, Renzo G; Hakimi, A Ari; Giuliani, Virginia; Heffernan, Timothy P; Viale, Andrea; Bristow, Christopher A; Tannir, Nizar M; Carugo, Alessandro; Genovese, Giannicola.
Afiliação
  • Perelli L; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LPerelli@mdanderson.org.
  • Carbone F; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang L; Nerviano Medical Sciences, NMS Group Spa, Milan, Italy.
  • Huang JK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Le C; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khan H; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Citron F; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Del Poggetto E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gutschner T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tomihara H; Junior Research Group 'RNA Biology and Pathogenesis', Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany.
  • Soeung M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Minelli R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Srinivasan S; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Peoples M; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lam TNA; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lundgren S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Xia R; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhu C; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mohamed AMT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sircar K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sgambato A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao J; Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Jonasch E; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Draetta GF; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bakouny Z; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Choueiri T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Msaouel P; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Litchfield K; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Turajlic S; Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA.
  • Wang L; The Francis Crick Institute, London, UK.
  • Chen YB; The Francis Crick Institute, London, UK.
  • Di Natale RG; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hakimi AA; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Giuliani V; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Heffernan TP; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Viale A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bristow CA; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tannir NM; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carugo A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Genovese G; TRACTION platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Cancer ; 4(7): 984-1000, 2023 07.
Article em En | MEDLINE | ID: mdl-37365326
ABSTRACT
Molecular routes to metastatic dissemination are critical determinants of aggressive cancers. Through in vivo CRISPR-Cas9 genome editing, we generated somatic mosaic genetically engineered models that faithfully recapitulate metastatic renal tumors. Disruption of 9p21 locus is an evolutionary driver to systemic disease through the rapid acquisition of complex karyotypes in cancer cells. Cross-species analysis revealed that recurrent patterns of copy number variations, including 21q loss and dysregulation of the interferon pathway, are major drivers of metastatic potential. In vitro and in vivo genomic engineering, leveraging loss-of-function studies, along with a model of partial trisomy of chromosome 21q, demonstrated a dosage-dependent effect of the interferon receptor genes cluster as an adaptive mechanism to deleterious chromosomal instability in metastatic progression. This work provides critical knowledge on drivers of renal cell carcinoma progression and defines the primary role of interferon signaling in constraining the propagation of aneuploid clones in cancer evolution.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos